1932

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive and generally incurable cancer. Current anti-MPM chemotherapy-based treatments are only marginally effective, and long-term survival remains an unmet goal. Nonetheless, in selected cases, personalized surgery-based multimodality treatments (MMT) have been shown to significantly extend survival. The design of MMT and selection of patients are challenging, and optimal results require accurate presurgical diagnosis, staging, and risk stratification. Further, meticulous surgical techniques and advanced radiation protocols must be applied. We review key principles and evolving concepts in the care of MPM patients with a focus on the expanding role of MMT in MPM.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-041316-085813
2018-01-29
2024-04-13
Loading full text...

Full text loading...

/deliver/fulltext/med/69/1/annurev-med-041316-085813.html?itemId=/content/journals/10.1146/annurev-med-041316-085813&mimeType=html&fmt=ahah

Literature Cited

  1. Chirieac LR, Barletta JA, Yeap BY. 1.  et al. 2013. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J. Clin. Oncol. 31:4544–49 [Google Scholar]
  2. Cugell DW, Kamp DW. 2.  2004. Asbestos and the pleura: a review. Chest 125:1103–17 [Google Scholar]
  3. Farioli A, Ottone M, Morganti AG. 3.  et al. 2016. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med 5:950–59 [Google Scholar]
  4. Testa JR, Cheung M, Pei J. 4.  et al. 2011. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43:1022–25 [Google Scholar]
  5. Beebe-Dimmer JL, Fryzek JP, Yee CL. 5.  et al. 2016. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival. Clin. Epidemiol. 8:743–50 [Google Scholar]
  6. Rusch VW, Chansky K, Kindler HL. 6.  et al. 2016. The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma. J. Thorac. Oncol. 11:2112–19 [Google Scholar]
  7. Sugarbaker DJ, Gill RR, Yeap BY. 7.  et al. 2013. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J. Thorac. Cardiovasc. Surg. 145:955–63 [Google Scholar]
  8. Bolukbas S, Manegold C, Eberlein M. 8.  et al. 2011. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 71:75–81 [Google Scholar]
  9. de Perrot M, Feld R, Leighl NB. 9.  et al. 2016. Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 151:468–73 [Google Scholar]
  10. Cao C, Tian D, Manganas C. 10.  et al. 2012. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann. Cardiothorac. Surg. 1:428–37 [Google Scholar]
  11. Burt BM, Ali SO, DaSilva MC. 11.  et al. 2013. Clinical indications and results after chest wall resection for recurrent mesothelioma. J. Thorac. Cardiovasc. Surg. 146:1373–79 [Google Scholar]
  12. Waller DA, Tenconi S. 12.  2017. Surgery as part of radical treatment for malignant pleural mesothelioma. Curr. Opin. Pulm. Med. 23:334–38 [Google Scholar]
  13. Galateau-Salle F, Churg A, Roggli V, Travis WD. 13. World Health Organization Committee for Tumors of the Pleura. 2016. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J. Thorac. Oncol 11:142–54 [Google Scholar]
  14. Friedberg JS, Simone CB 2nd, Culligan MJ. 14.  et al. 2017. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann. Thorac. Surg. 103:3912–19 [Google Scholar]
  15. Lang-Lazdunski L, Bille A, Papa S. 15.  et al. 2015. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J. Thorac. Cardiovasc. Surg. 149:558–65 [Google Scholar]
  16. Sugarbaker DJ, Wolf AS, Chirieac LR. 16.  et al. 2011. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur. J. Cardiothorac. Surg. 40:298–303 [Google Scholar]
  17. van Zandwijk N, Clarke C, Henderson D. 17.  et al. 2013. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J. Thorac. Dis. 5:E254–307 [Google Scholar]
  18. Bueno R, Reblando J, Glickman J. 18.  et al. 2004. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann. Thorac. Surg. 78:1774–76 [Google Scholar]
  19. Hallifax RJ, Corcoran JP, Ahmed A. 19.  et al. 2014. Physician-based ultrasound-guided biopsy for diagnosing pleural disease. Chest 146:1001–6 [Google Scholar]
  20. Metintas M, Yildirim H, Kaya T. 20.  et al. 2016. CT scan-guided Abrams’ needle pleural biopsy versus ultrasound-assisted cutting needle pleural biopsy for diagnosis in patients with pleural effusion: a randomized, controlled trial. Respiration 91:156–63 [Google Scholar]
  21. Welch BT, Eiken PW, Atwell TD. 21.  et al. 2017. A single-institution experience in percutaneous image-guided biopsy of malignant pleural mesothelioma. Cardiovasc. Intervent. Radiol. 40:860–63 [Google Scholar]
  22. Kao SC, Yan TD, Lee K. 22.  et al. 2011. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J. Thorac. Oncol. 6:602–5 [Google Scholar]
  23. Baas P, Fennell D, Kerr KM. 23.  et al. 2015. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26:Suppl. 5v31–v39 [Google Scholar]
  24. Bueno R, Stawiski EW, Goldstein LD. 24.  et al. 2016. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48:407–16 [Google Scholar]
  25. Nowak AK, Chansky K, Rice DC. 25.  et al. 2016. The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J. Thorac. Oncol. 11:2089–99 [Google Scholar]
  26. Pass H, Giroux D, Kennedy C. 26.  et al. 2016. The IASLC Mesothelioma Staging Project: improving staging of a rare disease through international participation. J. Thorac. Oncol. 11:2082–88 [Google Scholar]
  27. Rice D, Chansky K, Nowak A. 27.  et al. 2016. The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J. Thorac. Oncol. 11:2100–11 [Google Scholar]
  28. Dearbhaile CC. Constantinidou A, Sundar R28.  et al. 2017. Patterns of metastases in malignant pleural mesothelioma in the modern era: redefining the spread of an old disease. J. Clin. Oncol. 35:Suppl.8556 (Abstr.) [Google Scholar]
  29. Gill RR, Richards WG, Yeap BY. 29.  et al. 2012. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. Am. J. Roentgenol. 198:359–63 [Google Scholar]
  30. Sugarbaker DJ, Richards WG, Bueno R. 30.  2014. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann. Surg. 260:577–80 [Google Scholar]
  31. Kitajima K, Doi H, Kuribayashi K. 31.  et al. 2017. Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. Eur. J. Radiol. 86:176–83 [Google Scholar]
  32. Klabatsa A, Chicklore S, Barrington SF. 32.  et al. 2014. The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur. J. Nucl. Med. Mol. Imag. 41:276–82 [Google Scholar]
  33. Wald O, Sugarbaker DJ. 33.  2017. Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient. J. Thorac. Dis. 9:485–89 [Google Scholar]
  34. Alvarez JM, Hasani A, Segal A. 34.  et al. 2009. Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J. Surg. 79:734–38 [Google Scholar]
  35. Nakas A, Black E, Entwisle J. 35.  et al. 2010. Surgical assessment of malignant pleural mesothelioma: Have we reached a critical stage?. Eur. J. Cardiothorac. Surg. 37:1457–63 [Google Scholar]
  36. Rice DC, Erasmus JJ, Stevens CW. 36.  et al. 2005. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann. Thorac. Surg. 80:1988–92 [Google Scholar]
  37. Sorensen JB, Ravn J, Loft A. 37.  et al. 2008. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur. J. Cardiothorac. Surg. 34:1090–96 [Google Scholar]
  38. Rusch V, Baldini EH, Bueno R. 38.  et al. 2013. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J. Thorac. Cardiovasc. Surg. 145:909–10 [Google Scholar]
  39. Rusch VW, Giroux D, Kennedy C. 39.  et al. 2012. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J. Thorac. Oncol. 7:1631–39 [Google Scholar]
  40. Hoda MA, Klikovits T, Arns M. 40.  et al. 2016. Management of malignant pleural mesothelioma—part 2: therapeutic approaches. Consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin. Wochenschr. 128:618–26 [Google Scholar]
  41. Raynaud C, Greillier L, Mazieres J. 41.  et al. 2015. Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer 15:857–63 [Google Scholar]
  42. Vogelzang NJ, Rusthoven JJ, Symanowski J. 42.  et al. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2636–44 [Google Scholar]
  43. Zalcman G, Mazieres J, Margery J. 43.  et al. 2016. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387:1405–14 [Google Scholar]
  44. Marulli G, Faccioli E, Bellini A. 44.  et al. 2017. Induction chemotherapy versus post-operative adjuvant therapy for malignant pleural mesothelioma. Expert Rev. Respir. Med. 11:8649–60 [Google Scholar]
  45. Sugarbaker DJ, Wolf AS. 45.  2010. Surgery for malignant pleural mesothelioma. Expert Rev. Respir. Med. 4:363–72 [Google Scholar]
  46. Weder W, Opitz I, Stahel R. 46.  2009. Multimodality strategies in malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 21:172–76 [Google Scholar]
  47. Patel JD, Hensing TA, Rademaker A. 47.  et al. 2009. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 27:3284–89 [Google Scholar]
  48. Paz-Ares L, de Marinis F, Dediu M. 48.  et al. 2012. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247–55 [Google Scholar]
  49. van den Bogaert DP, Pouw EM, van Wijhe G. 49.  et al. 2006. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J. Thorac. Oncol. 1:25–30 [Google Scholar]
  50. Jing XQ, Zhou L, Sun XD. 50.  et al. 2016. Pemetrexed maintenance therapy following bevacizumab-containing first-line chemotherapy in advanced malignant pleural mesothelioma: a case report and literatures review. Medicine 95:e3351 [Google Scholar]
  51. Rosenzweig KE, Giraud P. 51.  2017. Radiation therapy for malignant pleural mesothelioma. Cancer Radiother 21:73–76 [Google Scholar]
  52. Cho BC, Feld R, Leighl N. 52.  et al. 2014. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J. Thorac. Oncol. 9:397–402 [Google Scholar]
  53. Rusch VW, Rimner A, Adusumilli PS. 53.  2016. SMART or simply bold?. J. Thorac. Cardiovasc. Surg. 151:476–77 [Google Scholar]
  54. Gomez DR, Hong DS, Allen PK. 54.  et al. 2013. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J. Thorac. Oncol. 8:238–45 [Google Scholar]
  55. Shaikh F, Zauderer MG, von Reibnitz D. 55.  et al. 2017. Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma. J. Thorac. Oncol. 12:993–1000 [Google Scholar]
  56. Hasegawa S, Okada M, Tanaka F. 56.  et al. 2016. Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). Int. J. Clin. Oncol. 21:3523–30 [Google Scholar]
  57. Stahel RA, Riesterer O, Xyrafas A. 57.  et al. 2015. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 16:1651–58 [Google Scholar]
  58. Rimner A, Zauderer MG, Gomez DR. 58.  et al. 2016. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J. Clin. Oncol. 34:2761–68 [Google Scholar]
  59. Rimner A, Simone CB 2nd, Zauderer MG. 59.  et al. 2016. Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?. Lancet Oncol 17:e43–e44 [Google Scholar]
  60. Rice D, Rusch V, Pass H. 60.  et al. 2011. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J. Thorac. Oncol. 6:1304–12 [Google Scholar]
  61. Minatel E, Trovo M, Polesel J. 61.  et al. 2014. Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up. Lung Cancer 83:78–82 [Google Scholar]
  62. Krug LM, Pass HI, Rusch VW. 62.  et al. 2009. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 27:3007–13 [Google Scholar]
  63. Burt BM, Cameron RB, Mollberg NM. 63.  et al. 2014. Malignant pleural mesothelioma and the Society of Thoracic Surgeons Database: an analysis of surgical morbidity and mortality. J. Thorac. Cardiovasc. Surg. 148:30–35 [Google Scholar]
  64. Cao C, Tian D, Park J. 64.  et al. 2014. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83:240–45 [Google Scholar]
  65. Cao C, Tian DH, Pataky KA, Yan TD. 65.  2013. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer 81:319–27 [Google Scholar]
  66. Taioli E, Wolf AS, Flores RM. 66.  2015. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann. Thorac. Surg. 99:472–80 [Google Scholar]
  67. Baldini EH, Richards WG, Gill RR. 67.  et al. 2015. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 149:1374–81 [Google Scholar]
  68. Sugarbaker DJ. 68.  2017. A phase I trial of extrapleural pneumonectomy or pleurectomy/decortication, intrathoracic/intraperitoneal hyperthermic chemotherapy cisplatin and gemcitabine with intravenous aminofostine and sodium thiosulfate cytoprotection for patients with resectable malignant pleural mesothelioma Presented at Am. Assoc. Thorac. Surg. Meet., Apr. 29–May 3 Boston, MA:
  69. Alley EW, Lopez J, Santoro A. 69.  et al. 2017. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 18:623–30 [Google Scholar]
  70. Ceresoli GL, Mantovani A. 70.  2017. Immune checkpoint inhibitors in malignant pleural mesothelioma. Lancet Oncol 18:559–61 [Google Scholar]
  71. Soo RA, Stone EC, Cummings KM. 71.  et al. 2017. Scientific advances in thoracic oncology 2016. J. Thorac. Oncol. 12:81183–209 [Google Scholar]
  72. Zauderer MG, Dao T, Rusch VW. 72.  et al. 2016. Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy. J. Clin. Oncol. 34:8519 (Abstr.) [Google Scholar]
  73. Hassan R, Thomas A, Alewine C. 73.  et al. 2016. Mesothelin immunotherapy for cancer: ready for prime time?. J. Clin. Oncol. 34:4171–79 [Google Scholar]
  74. McCormack PL. 74.  2015. Nintedanib: first global approval. Drugs 75:129–39 [Google Scholar]
  75. Scagliotti GV, Gaafar R, Nowak A. 75.  et al. 2016. P2.01: LUME-MeSO: Phase II/III study of nintedanib + pemetrexed/cisplatin in patients with malignant pleural mesothelioma: track: SCLC, mesothelioma, thymoma. J. Thorac. Oncol. 11:S216 [Google Scholar]
  76. Tsao AS, Moon J, Wistuba II. 76.  et al. 2017. Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905). J. Thorac. Oncol. 12:81299–308 [Google Scholar]
/content/journals/10.1146/annurev-med-041316-085813
Loading
/content/journals/10.1146/annurev-med-041316-085813
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error